Mechanistic Dissection of the Falconi Anemia Pathway of DNA Damage Response and Repair
法尔科尼贫血 DNA 损伤反应和修复途径的机制剖析
基本信息
- 批准号:9899099
- 负责人:
- 金额:$ 37.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-01-01 至 2022-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdvanced Malignant NeoplasmAldehydesAnemiaAreaBRCA1 ProteinBRCA1 geneBRCA2 geneBiochemicalBiologicalBiologyBreastCancer BiologyCellsChemicalsChromosome ArmChromosome FragilityChromosomesCommunitiesComplexDNADNA CrosslinkingDNA Crosslinking AgentDNA DamageDNA RepairDNA Repair PathwayDNA biosynthesisDNA lesionDefectDeubiquitinationDevelopmentDiagnosisDiseaseDissectionEnsureEtiologyEventExhibitsFanconi Anemia pathwayFanconi anemia proteinFanconi&aposs AnemiaFundingGenesGeneticGenetic TranscriptionGenomeGenomic InstabilityGenomicsGrantHereditary Breast CarcinomaHumanHypersensitivityID2 geneIncidenceJoint VenturesLicensingLightLinkMaintenanceMalignant NeoplasmsMediatingModelingMonoubiquitinationMotorMutationNucleic Acid BindingNucleic AcidsPancreasPancytopeniaPathogenicityPathway interactionsPatientsPhenotypePlayPredispositionPreventionProcessProteinsRNARad51 recombinaseRadiationRegulationResearch PersonnelResolutionResourcesRoleSignal TransductionStructureStructure-Activity RelationshipSystemTestingTumor SuppressionUbiquitinationWorkcancer preventioncancer therapycausal variantcohortgenotoxicityhelicasehomologous recombinationimprovedin vivoinhibitor/antagonistinsightmultidisciplinarynovelprotein complexrepairedreplication stressresearch studyresponsestemsuccesstumorigenesis
项目摘要
Project Summary
Proteins from the Fanconi anemia (FA) pathway play an integral role in DNA repair by homologous
recombination (HR). FA is a multigenic disorder marked by progressive bone marrow failure and a
strong cancer predisposition. Numerous studies have linked mutations in FA genes to familial breast,
pancreatic, and other cancers, and have also provided ample evidence to implicate silencing of FA
genes in the etiology of sporadic cancers. FA cells are hypersensitive to radiation and other DNA
damaging agents, DNA crosslinking chemicals and reactive aldehydes in particular, prone to DNA
replicative stress, and exhibit chromosome fragility. These phenotypic manifestations stem from
defects in DNA damage signaling and repair, and FA protein functional and physical interactions have
indicated an important link to the familial breast cancer proteins BRCA1 and BRCA2. The
involvement of the FA/BRCA-dependent DNA damage response in cancer suppression underscores
the need to understand the mechanistic underpinnings of this genome maintenance pathway.
In this project, we will employ a combination of biochemical and in vivo approaches to test the novel
hypotheses that the FA pathway coordinates the prevention and resolution of genotoxic structures
resulting from aberrant transcription events and HR. Aim 1 will focus on the mechanism whereby the
ID2 complex and UAF1-containing complexes engage nucleic acid containing structures and activate
HR. Aim 2 will explore how the FANCM-BLM axis resolves pathogenic RNA containing and other
nucleic acid intermediates in a way that regulates HR activities. The success of this project is
assured by the complementary expertise of the two participating Yale groups, led by Dr Patrick Sung
and Dr Gary Kupfer, and an exceptionally strong collaborative framework within the broader Yale
community. In addition, the PIs have enlisted two investigators, Dr. Claudia Wiese and Dr. Andres
Aguilera, whose expertise will even more elegantly allow the team to interrogate this novel area of
genomic instability. These attributes help ensure that findings of the highest possible impact will be
obtained. Since the biology of FA intersects with cancer biology in general, our project promises to
shed light on critical processes of genomic surveillance as well as common themes of oncogenesis.
We expect our studies to yield insight into common pathways of cancer and to identify novel targets
for manipulation in cancer therapy.
项目概要
来自范可尼贫血 (FA) 途径的蛋白质在同源 DNA 修复中发挥着不可或缺的作用
重组(HR)。 FA 是一种多基因疾病,其特征是进行性骨髓衰竭和
强烈的癌症倾向。许多研究已将 FA 基因突变与家族性乳房联系起来,
胰腺癌和其他癌症,并且还提供了充分的证据表明 FA 沉默
散发性癌症病因学中的基因。 FA 细胞对辐射和其他 DNA 高度敏感
损伤剂、DNA 交联化学物质和活性醛,特别是容易对 DNA 产生影响的物质
复制应激,并表现出染色体脆弱性。这些表型表现源于
DNA 损伤信号传导和修复以及 FA 蛋白功能和物理相互作用的缺陷
表明与家族性乳腺癌蛋白 BRCA1 和 BRCA2 存在重要联系。这
FA/BRCA 依赖性 DNA 损伤反应在癌症抑制中的参与强调
需要了解这种基因组维护途径的机制基础。
在这个项目中,我们将采用生化和体内方法相结合的方法来测试新型
假设 FA 途径协调基因毒性结构的预防和解决
由异常转录事件和 HR 引起的。目标 1 将重点关注机制
ID2 复合物和包含 UAF1 的复合物接合包含核酸的结构并激活
人力资源。目标 2 将探索 FANCM-BLM 轴如何解决含有和其他物质的致病性 RNA
核酸中间体以调节 HR 活动的方式。这个项目的成功在于
由帕特里克·宋博士领导的两个参与耶鲁小组的互补专业知识保证了这一点
和加里·库普弗博士,以及更广泛的耶鲁大学内部异常强大的合作框架
社区。此外,PI 还招募了两名调查员,Claudia Wiese 博士和 Andres 博士
阿奎莱拉(Aguilera)的专业知识将使团队能够更优雅地探究这个新领域
基因组不稳定。这些属性有助于确保具有最大可能影响的调查结果
获得。由于 FA 生物学与一般癌症生物学有交叉,我们的项目承诺
阐明基因组监测的关键过程以及肿瘤发生的常见主题。
我们希望我们的研究能够深入了解癌症的常见途径并确定新的靶点
用于癌症治疗中的操作。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gary M. Kupfer其他文献
Mechanism of PARP inhibitor resistance and potential overcoming strategies
- DOI:
10.1016/j.gendis.2023.02.014 - 发表时间:
2023-03-01 - 期刊:
- 影响因子:6.8
- 作者:
Xiaoyuan Fu;Ping Li;Qi Zhou;Ruyuan He;Guannan Wang;Shiya Zhu;A. Bagheri;Gary M. Kupfer;Huadong Pei;Juanjuan Li - 通讯作者:
Juanjuan Li
The FANCI/FANCD2 complex links DNA damage response to R-loop regulation through SRSF1-mediated mRNA export
FANCI/FANCD2 复合物通过 SRSF1 介导的 mRNA 输出将 DNA 损伤反应与 R 环调节联系起来
- DOI:
10.1016/j.celrep.2023.113610 - 发表时间:
2024-01-01 - 期刊:
- 影响因子:8.8
- 作者:
Anne Olazabal;Boxue He;Youngho Kwon;Abhishek K. Gupta;Arijit Dutta;Yuxin Huang;Prajwal Boddu;Zhuobin Liang;Fengshan Liang;Yaqun Teng;Li Lan;Xiaoyong Chen;Huadong Pei;Manoj M. Pillai;Patrick Sung;Gary M. Kupfer - 通讯作者:
Gary M. Kupfer
Gary M. Kupfer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gary M. Kupfer', 18)}}的其他基金
Mechanistic Dissection of the Fanconi Anemia Pathway of DNA Damage Response and R
DNA 损伤反应和 R 范可尼贫血途径的机制剖析
- 批准号:
8505689 - 财政年份:2013
- 资助金额:
$ 37.18万 - 项目类别:
Mechanistic Dissection of the BRCA1-SETX-dependent Pathway of R-loop Avoidance and Genome Maintenance
R 环避免和基因组维护的 BRCA1-SETX 依赖性途径的机制剖析
- 批准号:
10537108 - 财政年份:2013
- 资助金额:
$ 37.18万 - 项目类别:
Mechanistic Dissection of the Fanconi Anemia Pathway of DNA Damage Response and R
DNA 损伤反应和 R 范可尼贫血途径的机制剖析
- 批准号:
8826073 - 财政年份:2013
- 资助金额:
$ 37.18万 - 项目类别:
Mechanistic Dissection of the Fanconi Anemia Pathway of DNA Damage Response and R
DNA 损伤反应和 R 范可尼贫血途径的机制剖析
- 批准号:
8641673 - 财政年份:2013
- 资助金额:
$ 37.18万 - 项目类别:
Mechanistic Dissection of the BRCA1-SETX-dependent Pathway of R-loop Avoidance and Genome Maintenance
R 环避免和基因组维护的 BRCA1-SETX 依赖性途径的机制剖析
- 批准号:
10641022 - 财政年份:2013
- 资助金额:
$ 37.18万 - 项目类别:
HTLV I Tax1 protein chemosensitization of p53 mutant tumors
HTLV I Tax1 蛋白对 p53 突变肿瘤的化疗增敏
- 批准号:
8053781 - 财政年份:2010
- 资助金额:
$ 37.18万 - 项目类别:
HTLV I Tax1 protein chemosensitization of p53 mutant tumors
HTLV I Tax1 蛋白对 p53 突变肿瘤的化疗增敏
- 批准号:
7872281 - 财政年份:2010
- 资助金额:
$ 37.18万 - 项目类别:
The Fanconi Anemia Core and D2 Complexes
Fanconi 贫血核心和 D2 复合物
- 批准号:
7632267 - 财政年份:2000
- 资助金额:
$ 37.18万 - 项目类别:
FANCD2 interaction with mismatch repair proteins and MCM2-7
FANCD2 与错配修复蛋白和 MCM2-7 的相互作用
- 批准号:
8438399 - 财政年份:2000
- 资助金额:
$ 37.18万 - 项目类别:
The Fanconi Anemia Core and D2 Complexes
Fanconi 贫血核心和 D2 复合物
- 批准号:
7440298 - 财政年份:2000
- 资助金额:
$ 37.18万 - 项目类别:
相似海外基金
Phase Ib/II study of safety and efficacy of EZH2 inhibitor, tazemetostat, and PD-1 blockade for treatment of advanced non-small cell lung cancer
EZH2 抑制剂、他泽美司他和 PD-1 阻断治疗晚期非小细胞肺癌的安全性和有效性的 Ib/II 期研究
- 批准号:
10481965 - 财政年份:2024
- 资助金额:
$ 37.18万 - 项目类别:
Preserving Physical Function in Older Adults with Cancer: Impact of an Optimizing Nutrition Intervention Applied Before and After Surgery
保留患有癌症的老年人的身体功能:手术前后应用优化营养干预的影响
- 批准号:
10643468 - 财政年份:2023
- 资助金额:
$ 37.18万 - 项目类别:
Tumor and immune determinants of effective anti-tumor immunity in renal cell carcinoma
肾细胞癌有效抗肿瘤免疫的肿瘤和免疫决定因素
- 批准号:
10638907 - 财政年份:2023
- 资助金额:
$ 37.18万 - 项目类别:
Understanding resistance mechanisms to protein arginine methyltransransferase Inhibitors in Lymphoma
了解淋巴瘤对蛋白精氨酸甲基转移酶抑制剂的耐药机制
- 批准号:
10668754 - 财政年份:2023
- 资助金额:
$ 37.18万 - 项目类别: